key: cord-0802839-8qa9lira
authors: Haage, V. C.; Ferreira de Oliveira-Filho, E.; Moreira-Soto, A.; Kühne, A.; Fischer, C.; Sacks, J.; Corman, V. M.; Müller, M. A.; Drosten, C.; Drexler, J. F.
title: Impaired performance of SARS-CoV-2 antigen-detecting rapid tests at elevated temperatures
date: 2021-01-06
journal: nan
DOI: 10.1101/2021.01.06.21249314
sha: 4f28770a309c401275170a9fd74a3111f5500c9f
doc_id: 802839
cord_uid: 8qa9lira

Rapid antigen-detecting tests (Ag-RDTs) can complement molecular diagnostics for COVID-19. The recommended temperature for storage of SARS-CoV-2 Ag-RDTs ranges between 5-30{degrees}C. In many countries that would benefit from SARS-CoV-2 Ag-RDTs, mean temperatures exceed 30{degrees}C. We assessed analytical sensitivity and specificity of eleven commercially available SARS-CoV-2 Ag-RDTs using different storage and operational temperatures, including (i) long-term storage and testing at recommended conditions, (ii) recommended storage conditions followed by 10 minutes exposure to 37{degrees}C and testing at 37{degrees}C and (iii) 3 weeks storage followed by testing at 37{degrees}C. The limits of detection of SARS-CoV-2 Ag-RDTs under recommended conditions ranged from 8.2x105-7.9x107 genome copies/ml of infectious SARS-CoV-2 cell culture supernatant. Despite long-term storage at recommended conditions, 10 minutes pre-incubation of Ag-RDTs and testing at 37{degrees}C resulted in about ten-fold reduced sensitivity for 46% of SARS-CoV-2 Ag-RDTs, including both Ag-RDTs currently listed for emergency use by the World Health Organization. After 3 weeks of storage at 37{degrees}C, 73% of SARS-CoV-2 Ag-RDTs exhibited about ten-fold reduced sensitivity. Specificity of SARS-CoV-2 Ag-RDTs using cell culture-derived human coronaviruses HCoV-229E and HCoV-OC43 was not affected by storage and testing at 37{degrees}C. In summary, short- and long-term exposure to elevated temperatures likely impairs sensitivity of several SARS-CoV-2 Ag-RDTs that may translate to false-negative test results at clinically relevant virus concentrations compatible with inter-individual transmission. Ensuring appropriate transport and storage conditions, and development of tests that are more robust across temperature fluctuations will be important for accurate use of SARS-CoV-2 Ag-RDTs in tropical settings.

Advantages of SARS-CoV-2 antigen-detecting rapid diagnostic tests (Ag-RDTs) include 46 fast results and their applicability on site without dependence on laboratory settings. RDTs are not intended to replace real-time RT-PCR as the gold standard for SARS-CoV-48 2 diagnostics (1, 2), but can be deployed for surveillance in high-risk environments or 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. ; https://doi. org/10.1101 org/10. /2021 To validate the performance of SARS-CoV-2 Ag-RDT in tropical settings, we compared 68 analytical sensitivity and specificity of eleven SARS-CoV-2 Ag-RDTs using recommended 69 and elevated temperatures. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 6, 2021. For determination of the limit of detection (LOD), a SARS-CoV-2 stock (3.1x10 9 copies/ml) 98 was serially diluted in plain DMEM and 5µl/dilution were added to the extraction buffer of CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. ; https://doi.org/10. 1101 /2021 Analytical specificity 113 Specificity was tested using cell culture supernatant of HCoV-229E and HCoV-OC43, 114 grown on CaCo-2 cells. Quantification of viral stocks was performed by RT-PCR using an 115 in house protocol and photometrically quantified in vitro-transcribed RNA standards as 

Tests were performed according to the test-specific supplier instructions for use, except CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. 

At present, there are at least 119 SARS-CoV-2 Ag-RDTs commercially available (21).

Eleven of those SARS-CoV-2 rapid antigen tests were selected for temperature stability 140 validation based on the availability of clinical performance data (3), and manufacturing by 141 leading suppliers implying availability on the global market (Table 1) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. storage and test application in tropical settings (Figure 2) . 158 First, we determined analytical sensitivity at recommended conditions by determining the 159 limit of detection (LOD) of SARS-CoV-2 Ag-RDTs at room temperature using serial 160 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.06.21249314 doi: medRxiv preprint dilutions of SARS-CoV-2 cell culture supernatant (dilution range: 7.2x10 6 copies/ml to 161 3.1x10 9 copies/ml; Ag-RDT was calculated by correcting for the respective dilution factor. The dilution-factor 168 corrected limit of detection (LOD) for validated SARS-CoV-2 Ag-RDTs ranged from 169 8.2x10 5 copies/ml to 7.9x10 7 copies/ml of SARS-CoV-2 cell culture supernatant ( Table 2) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. 

1.2x10 6 1.4x10 6 7.0x10 6 1.1x10 6 7.9x10 7 4.6x10 7 8.2x10 5 1.4x10 6 1.0x10 6 1.0x10 6 1. The analytical sensitivity of about half of the evaluated SARS-CoV-2 Ag-RDTs (five out of 191 eleven; 46%) was already compromised by about ten-fold when tests were stored under 192 recommended conditions but exposed to 37°C for only ten minutes prior to testing at 37°C 193 (Figure 3) . After 19-21 days storage at 37°C and testing at 37°C, eight out of the eleven 194 SARS-CoV-2 Ag-RDTs (73%) showed an about ten-fold reduction in analytical sensitivity 195 when compared to recommended temperatures.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. Ag-RDTs. To guarantee temperature-regulated storage, a certain level of infrastructure is 237 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.06.21249314 doi: medRxiv preprint required, ideally air-conditioned facilities with temperature monitors and secured power 238 supply. However, these requirements are not realistic and appropriate concepts for 239 adequate storage in remote areas without electricity and rudimentary infrastructure will be 240 required.

Our study is limited by focusing on analytical test performance exclusively for reasons of 242 comparability of test results across the different conditions and based on limited access 243 to clinical samples. An additional limitation of our study is the use of duplicates for some 244 tests instead of a higher number of replicates, which was due to the limited availability of 245 all tests included in the study. Further studies will be required to assess test performance 246 upon tropical storage and application in tropical conditions using large numbers of clinical 247 samples. Additionally, not only the effect of elevated temperature but also the effect of 248 increased humidity on test performance will have to be assessed. Finally, future studies 249 documenting the impact of decreased temperature on test performance may also be 250 needed. Despite these limitations, our study presents a robust resource for further 251 validation studies as a high number of SARS-CoV-2 Ag-RDTs was included. Additionally, 252 our data on an overall impaired performance of Ag-RDTs at elevated temperatures are 253 consistent across tests and analytical sensitivity for several tests was identical upon usage 254 of either duplicates or higher numbers of replicates.

In sum, it was shown previously that clinically relevant virus concentrations of about 10 6 256 genome copies per ml suffice for virus isolation and culture and therefore serve as a 257 correlate for infectivity (35, 36) . Our study strongly suggests that short-and long-term 258 exposure to elevated temperatures may compromise sensitivity of SARS-CoV-2 Ag-RDTs 259 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. ; to an extent that may lead to false-negative test results at clinically relevant virus 260 concentrations, potentially enhancing SARS-CoV-2 spread in tropical settings. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 6, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 6, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 6, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted January 6, 2021. ; https://doi.org/10.1101/2021.01.06.21249314 doi: medRxiv preprint

SARS-CoV-2 pandemic: a review of molecular diagnostic tools 285 including sample collection and commercial response with associated advantages and 286 limitations

European Centre for Disease Prevention and Control S. 2020. Options for the use of 288 rapid antigen tests for COVID-19 in the EU/EEA and the UK

Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests

Clinical infectious diseases : an official 335 publication of the Infectious Diseases Society of America

Clinical bacteriology in low-resource settings: today's 338 solutions

The difficulties in obtaining reliable Zika virus 340 diagnostics

Considerations 342 for diagnostic COVID-19 tests

Technical guidance series (TGS) for WHO prequalification -345 diagnostic assessment panels for quality assurance and quality control of in vitro 346 diagnostic medical devices

A novel diagnostic target in the hepatitis C virus genome

Detection of 2019 novel coronavirus (2019-nCoV) 355 by real-time RT-PCR

Similar 361 virus spectra and seasonality in paediatric patients with acute respiratory disease, Ghana 362 and Germany

Typical epidemiology of respiratory 365 virus infections in a Brazilian slum

Mindestkriterien für SARS-CoV-2 Antigentests im Sinne 367 von § 1 Abs. 1 Satz 1 TestVO: Antigenschnelltests

The heat stability of Plasmodium lactate dehydrogenase-based 370 and histidine-rich protein 2-based malaria rapid diagnostic tests

The Comparative Accuracy of 8

Commercial Rapid Immunochromatographic Assays for the Diagnosis of Acute Dengue 375 Virus Infection

Malaria rapid 378 diagnostic test transport and storage conditions in Burkina Faso, Senegal, Ethiopia and 379 the Philippines

World Health Organization FfIND, Center for Disease Control and Prevention. 2014. 384 Malaria rapid diagnostic test performance. Results of WHO product testing of malaria 385 RDTs

The Use of Malaria Rapid Diagnostic Tests. Manila: World 387 Health Organization

Temperature and the field stability of a 390 dengue rapid diagnostic test in the tropics

Evaluation of Stability of In Vitro Diagnostic Reagents; Approved 392 Guidelines. Clinical and Laboratory Standards Institute EP25-A

Environmental Engineering Considerations and Laboratory Tests. 394 MIL-STD-810G

Evaluation of diagnostic tests 398 for infectious diseases: general principles

Virological assessment of 402 hospitalized patients with COVID-2019

SARS-CoV-2, SARS-CoV, and 404 MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a 405 systematic review and meta-analysis. The Lancet Microbe doi:10.1016/S2666-the author/funder, who has granted medRxiv a license to display the preprint in perpetuity